ClinicalTrials.gg
CompletedNCT01606007Updated May 15, 2017Results posted

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

A Phase 3 interventional study of Saxagliptin and Metformin XR in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 139 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,282
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.

Enrollment
4th of 74
1,282 · median 138
Started
2012
with 11 others
Phase 3
27 of 74
none open now
Registered
39th of 74
by date
Lead sponsor
48 of 74
AstraZeneca

Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 12 that started in 2012, is one of 27 in phase 3, and was the 39th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with Type 2 diabetes mellitus (T2DM) with ≥ 8.0% and ≤ 12.0%
  • Stable metformin therapy dose of ≥ 1500mg for at least 8 weeks prior to screening
  • (BMI) ≤ 45.0kg/m2

Exclusion criteria

Exclusion Criteria:

  • Estimated (eGFR) \< 60mL/min/1,73m2 and Serum Creatinine (Scr) ≥ 1.5 mg/dL in males or ≥ 1.4 mg/dL in females
  • Uncontrolled hypertension Systolic Blood Pressure (SBP) ≥ 160mmHg and/or Diastolic Blood Pressure (DBP) ≥ 100mmHg
  • Hepatic disease
  • Cardiovascular disease within 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,282 participants (actual)

Study arms

  • Active comparator
    Arm 1: Saxagliptin+Metformin XR+Placebo

    Drug: Saxagliptin · Drug: Metformin XR · Drug: Placebo matching with Dapagliflozin

  • Active comparator
    Arm 2: Dapagliflozin+Metformin XR+Placebo

    Drug: Metformin XR · Drug: Dapagliflozin · Drug: Placebo matching with Saxagliptin

  • Experimental
    Arm 3: Saxagliptin+Dapagliflozin+Metformin XR

    Drug: Saxagliptin · Drug: Metformin XR · Drug: Dapagliflozin

Interventions

  • Tablets, Oral, 5mg , Once daily, 24 weeks

    Also known as: Onglyza

  • Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks

    Also known as: Glucophage XR

  • Tablets, Oral, 10mg , Once daily, 24 weeks

    Also known as: BMS-512148

  • DrugPlacebo matching with Dapagliflozin

    Tablets, Oral, 0mg, Once daily, 24 weeks

  • DrugPlacebo matching with Saxagliptin

    Tablets, Oral, 0mg, Once daily, 24 weeks

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24

    HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.

    Time frame: Baseline (Week 0) and at Week 24

Secondary outcomes

  1. Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])

    Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PPG measurements were obtained at week 24 in the doubleblind period, including observations prior to rescue.

    Time frame: Baseline (Week 0) and at Week 24

  2. Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.

    Time frame: Baseline (Week 0) and at Week 24

  3. Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])

    Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.

    Time frame: At Week 24

  4. Adjusted Mean Change From Baseline in Body Weight at Week 24

    Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.

    Time frame: Baseline (Week 0) and at Week 24

07

Results

Posted Oct 20, 2015

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XR
Started176179179
Completed161160169
Not completed151910
Withdrew: Reason 'other' in the protocol011
Withdrew: Pregnancy011
Withdrew: Withdrawal by subject861
Withdrew: Adverse event011
Withdrew: Discontinue study treatment021
Withdrew: Lost to follow-up685
Withdrew: Poor/non-compliance100

Outcome measures

PrimaryAdjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24

HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.

Time frame:
Baseline (Week 0) and at Week 24
Reported as:
Mean · % HbA1c
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24
% HbA1cArm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XR
Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24-0.88 (-1.03 to -0.72)-1.20 (-1.35 to -1.04)-1.47 (-1.62 to -1.31)
Statistical analysis
  • Arm 1: Saxagliptin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · Mixed Models Analysis · p = <0.0001 (Primary endpoint was tested at alpha=0.05; significance was claimed only if Saxagliptin+Dapagliflozin+Metformin was superior to both Saxagliptin+Metformin and Dapagliflozin+Metformin.) · Mean difference (final values): -0.59 · 95% CI -0.81 to -0.37
  • Arm 2: Dapagliflozin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · Mixed Models Analysis · p = 0.0166 (Primary endpoint was tested at alpha=0.05; significance was claimed only if Saxagliptin+Dapagliflozin+Metformin was superior to both Saxagliptin+Metformin and Dapagliflozin+Metformin.) · Mean difference (final values): -0.27 · 95% CI -0.48 to -0.05
SecondaryAdjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])

Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PPG measurements were obtained at week 24 in the doubleblind period, including observations prior to rescue.

Time frame:
Baseline (Week 0) and at Week 24
Reported as:
Mean · MG/DL PPG
Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])
MG/DL PPGArm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XR
Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])-35.6 ± 3.510-70.4 ± 3.538-79.6 ± 3.426
Statistical analysis
  • Arm 1: Saxagliptin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · ANCOVA · p = <0.0001 (Each secondary endpoint was tested at alpha=0.05; significance was claimed only if Saxagliptin+Dapagliflozin+Metformin was superior to both Saxagliptin+Metformin and Dapagliflozin+Metformin.) · Mean difference (final values): -44.0 · 95% CI -53.7 to -34.3
  • Arm 2: Dapagliflozin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · ANCOVA · p = 0.0639 (Each secondary endpoint was tested at alpha=0.05; significance testing stops at the endpoint where p-value\>0.05.) · Mean difference (final values): -9.1 · 95% CI -18.8 to 0.5
SecondaryAdjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.

Time frame:
Baseline (Week 0) and at Week 24
Reported as:
Mean · mg/dL
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mg/dLArm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XR
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-14.0 (-19.6 to -8.4)-31.7 (-37.3 to -26.2)-37.8 (-43.2 to -32.3)
Statistical analysis
  • Arm 1: Saxagliptin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · Mean difference (final values): -23.8 · 95% CI -31.6 to -15.9ANCOVA was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\>0.05.
  • Arm 2: Dapagliflozin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · Mean difference (final values): -6.1 · 95% CI -13.8 to 1.7ANCOVA was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\>0.05.
SecondaryAdjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])

Therapeutic glycemic response is defined as HbA1c \<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.

Time frame:
At Week 24
Reported as:
Number · % of Participants
Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])
% of ParticipantsArm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XR
Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])18.3 (13.0 to 23.5)22.2 (16.1 to 28.3)41.4 (34.5 to 48.2)
Statistical analysis
  • Arm 1: Saxagliptin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · Mean difference in percentages: 23.1 · 95% CI 14.7 to 31.5Modified Logistic Regression was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\>0.05.
  • Arm 2: Dapagliflozin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · Mean difference in percentages: 19.1 · 95% CI 10.1 to 28.1Modified Logistic Regression was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\>0.05.
SecondaryAdjusted Mean Change From Baseline in Body Weight at Week 24

Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.

Time frame:
Baseline (Week 0) and at Week 24
Reported as:
Mean · Body weight Kg
Adjusted Mean Change From Baseline in Body Weight at Week 24
Body weight KgArm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XR
Adjusted Mean Change From Baseline in Body Weight at Week 240.00 (-0.48 to 0.49)-2.39 (-2.87 to -1.91)-2.05 (-2.52 to -1.58)
Statistical analysis
  • Arm 1: Saxagliptin+Metformin XR+Placebo vs Arm 3: Saxagliptin+Dapagliflozin+Metformin XR · Mean difference (final values): -2.05 · 95% CI -2.73 to -1.37ANCOVA was applied for comparison, but p-value was not reported because at least one prior test in the hierarchical testing procedure yielded p-value\>0.05.

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAXA + MET—6/176 (3.4%)0/176 (0%)
DAPA + MET—2/179 (1.1%)0/179 (0%)
SAXA + DAPA + MET—2/179 (1.1%)0/179 (0%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventSAXA + METDAPA + METSAXA + DAPA + MET
UMBILICAL HERNIAGastrointestinal disorders1/1760/1790/179
CHEST PAINGeneral disorders1/1760/1790/179
TOOTH INFECTIONInfections and infestations1/1760/1790/179
PATELLA FRACTUREInjury, poisoning and procedural complications1/1760/1790/179
HYPERKALAEMIAMetabolism and nutrition disorders1/1760/1790/179
ARTHRITISMusculoskeletal and connective tissue disorders1/1760/1790/179
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders1/1760/1790/179
DEEP VEIN THROMBOSISVascular disorders1/1760/1790/179
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/1760/1791/179
PANCREATITIS CHRONICGastrointestinal disorders0/1760/1791/179

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XRTotal
Mean54.6 ± 9.653.5 ± 9.753.4 ± 9.853.8 ± 9.7
Age, Customized
Age, Customized(participants)Arm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XRTotal
<65 years148158160466
>=65 years28211968
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XRTotal
Female829094266
Male948985268
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Arm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XRTotal
White121131120372
Black african/american22162260
Asian11101233
Other22222569
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Arm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XRTotal
Mean31.8 ± 5.14231.46 ± 5.32131.76 ± 4.78731.67 ± 5.080
T2DM duration
T2DM duration(years)Arm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XRTotal
Mean8.2 ± 5.527.4 ± 5.407.1 ± 5.047.6 ± 5.33
HbA1c
HbA1c(%)Arm 1: Saxagliptin+Metformin XR+PlaceboArm 2: Dapagliflozin+Metformin XR+PlaceboArm 3: Saxagliptin+Dapagliflozin+Metformin XRTotal
Mean9.03 ± 1.058.87 ± 1.168.92 ± 1.188.94 ± 1.13
08

Study locations

139 sites
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Central Alabama Research
    Homewood, Alabama 35244, United States
  • Terence T. Hart, Md
    Muscle Shoals, Alabama 35662, United States
  • International Institute Of Clinical Research
    Ozark, Alabama 36360, United States
  • Clinical Research Advantage
    Mesa, Arizona 85206, United States
  • Elite Clinical Studies, Llc
    Phoenix, Arizona 85018, United States
  • Genova Clinical Research
    Tucson, Arizona 85704, United States
  • Medical Investigations, Inc.
    Little Rock, Arkansas 72205, United States
  • Aureus Research, Inc.
    Little Rock, Arkansas 72211, United States
  • Southland Clinical Research Center, Inc.
    Fountain Valley, California 92708, United States
  • Torrance Clinical Research
    Lomita, California 90717, United States
  • National Research Inst
    Los Angeles, California 90057, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Diabetes Medical Center Of California
    Northridge, California 91325, United States
  • Mehrdad Kevin Ariani Md, Inc.
    Northridge, California 91325, United States
  • Lucita M. Cruz,Md.,Inc.
    Norwalk, California 90650, United States
  • Center For Clinical Trials, Llc.
    Paramount, California 90723, United States
  • Center For Clinical Trials Of Sacramento, Inc.
    Sacramento, California 95823, United States
  • Trinitas Research, Inc
    San Jose, California 95116, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Clinical Research Advantage
    Colorado Springs, Colorado 80906, United States
  • Infocus Clinical Research
    Denver, Colorado 80211, United States
  • Lynn Institute Of Denver
    Denver, Colorado 80246, United States
  • Southeast Clinical Research, Llc
    Chiefland, Florida 32626, United States
  • Clinical Therapeutics Corporation
    Coral Gables, Florida 33134, United States
  • Southeast Clinical Research, Llc
    Jacksonville, Florida 32216, United States
  • Fpa Clinical Research
    Kissimmee, Florida 34741, United States
  • Newphase Clinical Trials, Inc.
    Miami Beach, Florida 33140, United States
  • Clinical Research Of Miami, Inc.
    Miami, Florida 33126, United States
  • Advanced Pharma Cr, Llc
    Miami, Florida 33136, United States
  • Omega Research Consultants, Llc
    Orlando, Florida 32804, United States
  • Palm Harbor Medical Associates
    Palm Harbor, Florida 34684, United States
  • Andres Patron, Do Pa
    Pembroke Pines, Florida 33026, United States
  • Endocrine Research Solutions, Inc.
    Roswell, Georgia 30076, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607-4559, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Clinical Research Advantage
    Council Bluffs, Iowa 51503, United States
  • Horizon Research Group Of Opelousas, Llc
    Eunice, Louisiana 70535, United States
  • Associated Internal Medicine Specialists
    Battle Creek, Michigan 49015, United States
  • Harris And Associates, P.C.
    Detroit, Michigan 48235, United States
  • Patterson Medical Clinic
    Florissant, Missouri 63031, United States
  • Bellevue Family Practice
    Bellevue, Nebraska 68005, United States
  • Clinical Research Advantage
    Elkhorn, Nebraska 68022, United States
  • Clinical Research Advantage
    Fremont, Nebraska 68025, United States
  • Clinical Research Advantage
    Omaha, Nebraska 68130, United States
  • South Jersey Medical Associates, P.A.
    Blackwood, New Jersey 08012, United States
  • Central Jersey Health And Medical Research
    Elizabeth, New Jersey 07205, United States
  • Southgate Medical Group
    West Seneca, New York 14224, United States
  • Metrolina Internal Medicine
    Charlotte, North Carolina 28204, United States
  • Triad Clinical Trials, Llc
    Greensboro, North Carolina 27410, United States
  • Diabetes & Endocrinology Consultants
    Morehead City, North Carolina 28557, United States
  • Pmg Research Of Winston-Salem, Llc
    Winston-salem, North Carolina 27103, United States
  • Daystar Clinical Resarch, Inc.
    Akron, Ohio 44313, United States
  • Sterling Research Grp, Ltd.
    Cincinnati, Ohio 45246, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Primed Clinical Research
    Dayton, Ohio 45419, United States
  • Physicians Research, Inc.
    Zanesville, Ohio 43701, United States
  • Lynn Institute Of Norman
    Norman, Oklahoma 73069, United States
  • Willamette Valley Clinical Studies
    Eugene, Oregon 97404, United States
  • Oregon Clinical Research
    Portland, Oregon 97220, United States
  • Heritage Valley Medical Group
    Beaver, Pennsylvania 15009, United States
  • Wellmon Family Practice
    Shippensburg, Pennsylvania 17257, United States
  • Tlm Medical Services
    Columbia, South Carolina 29204, United States
  • Palmetto Clinical Trial Services Llc
    Fountain Inn, South Carolina 29644, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Pmg Research Of Knoxville
    Knoxville, Tennessee 37912, United States
  • Arlington Family Research Center, Inc.
    Arlington, Texas 76012, United States
  • Padre Coast Clinical Research
    Corpus Christi, Texas 78404, United States
  • Dallas Diabetes & Endocrine Center
    Dallas, Texas 75230-2548, United States
  • Excel Clinical Research, Llc
    Houston, Texas 77035, United States
  • North Hills Medical Research, Inc.
    North Richland Hills, Texas 76180, United States
  • Med-Olam Clinical Research
    Pasadena, Texas 77504, United States
  • Sam Clinical Research Center
    San Antoinio, Texas 78229, United States
  • Covenant Clinical Research, Pa
    San Antonio, Texas 78229, United States
  • Hillcrest Family Health Center
    Waco, Texas 76710, United States
  • Val R. Hansen, M.D.
    Bountiful, Utah 84010, United States
  • Highland Clinical Research
    Salt Lake City, Utah 84124, United States
  • Southwestern Vermont Med Cntr
    Bennington, Vermont 05201, United States
  • Hampton Roads Center For Clinical Research, Inc.
    Suffolk, Virginia 23435, United States
  • Local Institution
    Coquitlam, British Columbia V3K 3V9, Canada
  • Local Institution
    Winnipeg, Manitoba R3E3P4, Canada
  • Local Institution
    Brampton, Ontario L6T 0G1, Canada
  • Local Institution
    Smiths Falls, Ontario K7A 4W8, Canada
  • Local Institution
    Toronto, Ontario M9W 4L6, Canada
  • Local Institution
    Granby, Quebec J2G 8Z9, Canada
  • Local Institution
    Saskatoon, Saskatchewan S7K 3H3, Canada
  • Local Institution
    Quebec, G1N 4V3, Canada
  • Local Institution
    Bucheon, Gyeonggi-do 420-717, Korea, Republic of
  • Local Institution
    Sungnam-si, Gyeonggi-do 463-712, Korea, Republic of
  • Local Institution
    Daegu, 700-721, Korea, Republic of
  • Local Institution
    Incheon, 405-760, Korea, Republic of
  • Local Institution
    Seoul, 110-774, Korea, Republic of
  • Local Institution
    Seoul, 120-752, Korea, Republic of
  • Local Institution
    Seoul, 137-701, Korea, Republic of
  • Local Institution
    Guadalajara, Jalisco 44670, Mexico
  • Local Institution
    Cuautla, Morelos 62744, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64710, Mexico
  • Local Institution
    Merida, Yucatan 97070, Mexico

Showing the first 100 of 139 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142. Epub 2014 Oct 28. PubMed 25352655 ↗
  • Bailey CJ, Del Prato S, Wei C, Reyner D, Saraiva G. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. Diabetes Obes Metab. 2019 Nov;21(11):2564-2569. doi: 10.1111/dom.13841. Epub 2019 Aug 26. PubMed 31364269 ↗
  • Rosenstock J, Mathieu C, Chen H, Garcia-Sanchez R, Saraiva GL. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Arch Endocrinol Metab. 2018 Aug;62(4):424-430. doi: 10.20945/2359-3997000000056. PubMed 30304106 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2012
First posted
May 25, 2012
Start
Jul 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Oct 20, 2015
Last update
May 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01606007
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 25, 2012
Start date
Jul 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Oct 20, 2015
Last update
May 15, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Dapagliflozin

Start the discussion